Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in a previous publication [1] .
Clinical scenario
You are discussing with your colleagues in your institutional sleep medicine multidisciplinary team meeting the case of a 42-year-old obese man who despite having lost 55 kg following gastric bypass surgery over two years ago as well as previous uvulopalatopharyngoplasty and radiofrequency ablation to the tongue base, is still suffering from severe obstructive sleep apnoea with an apnoea hypopnoea index of 35 h
À1
. His body mass index has now stabilised to 32kgm -2 and he has failed to tolerate oral appliance and continuous positive airway pressure therapy. Drug-induced sleep endoscopy reveals residual multi-level collapse at the palate, tongue base, epiglottis, and hypopharynx. You are being asked whether transoral robotic surgery would have a role for this patient before recommending a tracheostomy in view of his obesity and previous treatment failures. You resolve to assess the literature yourself.
Three-part question
Is transoral robotic surgery a safe and effective multilevel treatment for obstructive sleep apnoea in obese patients following failure of conventional treatment(s)?
Search strategy
A literature search was performed using PubMed, Scopus, Ovid, Embase, and Cochrane databases using the terms: (transoral In addition, the reference lists of the relevant papers were searched. The search was current as of 1st June 2017.
Search outcome
Thirty nine papers were found using the reported search. Two authors (G.G. and A.K.) independently assessed the titles and abstracts of the identified articles to determine potential relevance. Any disagreement was resolved by discussion or with the opinion of the senior author (N.T.) After reviewing the abstracts, 37 papers were selected to be fully appraised in view of relevance and methods used. From these, 9 were irrelevant, 7 were review articles, 4 included a mixed patient cohort with some patients undergoing TORS and others non-robotic transoral surgical interventions for OSA, 4 described cadaveric studies, 3 did not allow distinction of obese and non-obese patients from the cohort to compare outcomes, 2 evaluated paediatric patients, one was in a language other than English, one only reported airway (i.e. volumetric as opposed to clinical) measures, and two were case reports (including the one article in a language other than English). Inclusion criteria included studies of any size, prospective or retrospective in design assessing the success of TORS in the treatment of OSA between obese and non-obese patients. Included studies must have been composed of adults undergoing TORS for OSA that had failed conventional treatment(s). Exclusion criteria involved studies evaluating paediatric patients, non-clinical studies (e.g. cadaveric or animal studies), and studies reporting non-clinical outcomes only (e.g. volumetric or airway measures). However, due to paucity of studies specifically comparing TORS outcomes for OSA in obese vs. non-obese patients, studies with a mixed cohort were included provided that it was possible to subgroup patients based on their BMI (and thus be able to compare their respective outcomes) in the data analysis and evidence synthesis. Review articles and articles not published in the English language were excluded. Based on design, number of patients and origin (high volume/specialised centres) 5 papers were chosen as representing the evidence to answer the clinical question.
Results
The results of the five papers (two prospective and three retrospective cohort studies) are summarised in Table 1 .
Discussion
TransOral Robotic Surgery (TORS) represents the latest addition to the armamentarium of Otorhinolaryngologists e Head and Neck Surgeons for the management of Obstructive Sleep Apnoea (OSA) [2] . Though the main treatment for OSA still remains Continuous Positive Airway Pressure (CPAP), patient adherence to CPAP has been shown to be particularly low, with a number of studies and audits reporting adherence rates below 50% [3e5]. With nonsurgical treatment modalities (i.e. CPAP or oral appliances), patients that fail this or refuse to comply with this often emphasise their frustration of having to use this every night and many prefer the possibility of a "one-stop fix" with surgical intervention [6] . As a result, surgery is regaining momentum in the management of OSA, especially in those patients intolerant of CPAP.
Contrary to 'conventional' (non-robotic) transoral surgical approaches, TORS offers superior visualisation and ergonomics by overcoming the difficulty associated with accessing the base of tongue (BOT) and hypopharynx. This renders TORS ideal for multilevel surgery obviating the need for open access -and its associated morbidity [7] . However, not all patients are suitable candidates for TORS with biometric measures determining patient suitability [8] . Taking into account the existing global obesity pandemic, a particularly relevant biometric measure is Body Mass Index (BMI) [9] . Obesity is closely interlinked with the development of OSA and constitutes the primary reason why OSA is now also seen as a public health problem affecting over 10% of the world's population [10] . Despite this, only a handful of studies have evaluated the success rate of TORS for OSA as a function of patient BMI [2,11e14] .
The reason for this paucity of evidence is threefold. Firstly, there is level I evidence to support CPAP as a highly effective (the 'gold standard') treatment for OSA e even at low levels of compliance [15] . Secondly, the results reported for the surgical treatment of OSA (in the pre-robotic surgery epoch) have been inconsistent and, as such, remain an area of intense debate [16] . This however is likely to be the result of poor patient selection combined with inability to address difficult-to-access areas due to 'line-of-sight' limitations associated with conventional transoral (microscopic and/or laser) surgery [2] . Thirdly, TORS e designed to overcome these limitations and thus offering a 'true' multilevel treatment e has only been around for just over 6 years as a surgical treatment option for OSA [17] . As more units take up TORS as a surgical treatment option for OSA in carefully selected patients and further long-term results from multicenter studies become available, the evidence base is likely to strengthen and provide answers to the existing questions on the topic.
In addition to the paucity of studies evaluating the role of TORS for OSA in the obese patient subgroup following failure of conventional treatment(s), those studies are characterised by marked heterogeneity. This heterogeneity extends beyond patient characteristics (e.g. in terms of severity of OSA and level of obstruction), to ) had significantly higher failure rates compared to non-obese (p < 0.01) One patient had a minor secondary haemorrhage, one patient had dysgeusia and two patients had odynophagia to solids Voice and swallowing worsened initially in first 2 week (p < 0.005) but returned to normal levels within 3 months Quality of life was improved 3 months after the procedure (p < 0.001) These include the effectiveness of TORS exceeding 75% in non-obese OSA patients (subject to correct patient selection), the negative effect of an increasing BMI on surgical 'success' and/or 'response' rates (independent of how these were defined in each study, please see text below and Table 1 for individual criteria employed in each study), and that beyond a BMI of 40kgm -2 , TORS has no role in the treatment of OSA with surgical response rates dropping to below 20%. Each study is discussed in depth below. In 2016, Arora et al. [2] conducted a prospective analysis of 14 patients (13 male, 1 female) who underwent TORS for OSA. All 14 patients underwent TORS BOT reduction and 10 also had wedge epiglottoplasty (depending on drug-induced sleep endoscopy (DISE) findings). Inclusion criteria comprised of a diagnosis of moderate-to-severe OSA diagnosed on polysomnography (PSG) and failure to tolerate conventional treatment (CPAP or mandibular advancement device e MAD). Moreover, BMI had to be below 35kgm -2 . Median follow up was 24 months (mean ¼ 18.9 ± 6.2, range 12e24) and mean pre-operative BMI was 28.7 ± 2.8kgm -2 .
Nine patients had previously undergone oropharyngeal procedures for their OSA. , morbidly obese excluded from the study) had significantly lower success rates compared to non-obese (53.3% vs. 75.4%, p < 0.01). Re-intubation, nasogastric tube (NGT) insertion or tracheostomy was not required in any case. Temporary complications included secondary haemorrhage 3 weeks post-TORS (1 patient), dysgeusia (1 patient), and odynophagia to solids (2 patients), all successfully managed conservatively. Patient Reported Outcome Measures (PROMs) including Quality of Life (QoL) were recorded revealing a significant improvement 3 months after TORS (67% vs. 86% on EQ-5D visual analogue scale, p < 0.01). Strengths of this study include the fact that it was prospective and the follow-up period was long. Limitations include the lack of a control group and small sample size.
Chiffer et al. [11] performed a prospective non-randomised study of 19 patients (16 male, 3 female) undergoing TORS for OSA. In addition to AHI, the authors measured the volumetric effect of TORS based on MRI and assessed whether any changes observed were associated with the success rate of the robotic procedures. Patients with significant comorbidities, an active infection, and those pregnant were excluded. All patients underwent DISE to determine the level(s) of obstruction. In all patients, TORS involved bilateral posterior hemiglossectomy with limited pharyngectomy and uvulopalatopharyngoplasty. Individual post-operative BMI was noted (mean 32.2kgm -2 , range 22.6e55.7kgm 50% decrease of pre-operative AHI in combination with postoperative AHI<20 h À1 ) and 12/18 patients (67%) were classified as surgical responders (defined only by a 50% decrease in preoperative AHI). Patients classified in the surgical success group experienced a significant mean drop in AHI of 52.9 ± 29.0 h À1 compared to the 4.5 ± 33.5 h À1 in those patients who did not meet the criteria (p ¼ 0.006). In terms of volumetric MRI measurements, there was an increase in airway volume following TORS at the retropalatal and total lateral wall levels that showed a statistically significant correlation with AHI (rho ¼ 0.69, p ¼ 0.0014, and rho ¼ 0.63, p ¼ 0.0121, respectively). When comparing obese and non-obese patients, no statistically significant difference was found in terms of surgical response (56.3% vs. 50.0%, p > 0.1). This was most likely due to the small sample size (n ¼ 19). However, the success rate in the non-morbidly obese patients (BMI ¼ 30-35kgm -2 ) was reported as 62.5%. Though this study was prospectively conducted and used PSG as well as volumetric data, it is characterised by a number of limitations. These include its small sample size, BMI changes not being controlled for, and bias related to clinicians analysing the volumetric MRI scans not being blinded to post-operative AHI values. Hoff et al. [12] retrospectively analysed 121 OSA patients (83 male, 38 female) that underwent TORS either to the tongue base alone or combined with other pharyngeal, palatal or nasal procedures. All patients had been trialled on CPAP and failed to tolerate (or declined) this. The success of TORS was defined as both a post-operative AHI<20 h À1 and a decrease in AHI by 50%. Lin et al. [13] performed a retrospective analysis of 39 patients (24 male, 15 female) that had undergone TORS for OSA. Of these, 11 (28.2%) underwent BOT reduction alone, 2 (5.1%) BOT reduction combined with uvulopalatopharyngoplasty (UPPP), 7 (17.9%) BOT reduction and epiglottectomy, and 19 (48.7%) BOT, UPPP, and epiglottectomy. All patients underwent DISE prior to surgery to identify the level(s) of obstruction and over half had undergone previous upper airway procedures for their OSA. The aim of this study was to look for predictors of success of TORS for OSA to assist patient selection. A variety of outcomes were recorded including AHI, ESS, BMI, and lowest oxygen saturation (LO 2 sat) among others. Follow-up was for a minimum of 4 months. BMI and AHI were classified into clinically relevant partitions. The authors demonstrated that a statistically significant difference continued to exist between the responders and non-responders for both BMI (p ¼ 0.000) and AHI (p ¼ 0.025 (2) , and adenoidectomy (1 patient). The study included patients that were diagnosed with moderate to severe OSA and had failed to tolerate conventional treatment. All patients underwent DISE to determine the level of obstruction in addition to PSG. Surgical success was interpreted as AHI<20 h À1 combined with a decrease of AHI by 50% and cure was defined as AHI<5 h
À1
. In 63% of patients, the intervention was considered successful according to these criteria, whilst 82.2% showed an improvement in their post-operative AHI and 16.9% were cured 3 months following TORS. The percentage of patients that had a successful TORS for OSA varied between the different Friedman stages, though, statistically significant differences between preand post-operative AHI were only seen in patients classified in Friedman stages 1 (p ¼ 0.02), 2 (p ¼ 0.0001), and 3 (p ¼ 0.0001). With regards to BMI, it was shown that patients with BMI<30kgm -2 had a success rate of 69.9% whilst for those with a BMI>30kgm -2 the success rate dropped to 51% (p ¼ 0.041). This is an important study due to the large number of patients evaluated and the fact that the role of BMI as a predictive tool was specifically assessed. Limitations include its retrospective nature and absence of a control group.
Clinical bottom line
With obesity acting as the main driver for OSA in adults, the two are closely interlinked constituting important public health problems. Existing treatments for OSA -primarily CPAP -though highly effective are poorly tolerated resulting in an adherence often below 50%. As such, surgery is regaining momentum, especially in those patients failing to tolerate CPAP. TORS enhances conventional transoral surgery and facilitates the multilevel treatment of OSA as a direct result of its superior visualisation and ergonomics. The number of obese patients referred for consideration of TORS for their OSA following failure of both CPAP and other surgical treatments is rapidly increasing and likely to continue doing so in the epoch of a global obesity pandemic.
The existing evidence, though characterised by a complete absence of randomised controlled studies, shows that preoperative BMI is a reliable predictor of success of TORS for OSA. The evidence also suggests that TORS is effective in over 75% of non-obese OSA patients (subject to correct patient selection), and despite the drop in success rates with increasing BMI, the success rate of TORS in the non-morbidly obese OSA group (BMI ¼ 30-35kgm -2 ) exceeds 50%. Though a 50% success rate may at first seem low, it is important to realize that this is a patient cohort suffering from a life-threatening disease with important socioeconomic consequences not only for them but also for their families and that following a series of treatment failures, these patients are left with no other option other than a tracheostomy. As such, TORS represents an important treatment in non-morbidly obese OSA patients following failure of conventional treatment(s).
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